Bert Vandeloo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bert Vandeloo has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Adel Aminian
Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Belgium (A.A.).
2 shared publications - Claudiu Ungureanu
Cardiovascular Jolimont Hospital La Louvière Belgium
2 shared publications - Jan Van der Heyden
Department of Cardiology, Sint Jan Hospital , Brugge
2 shared publications - Liesbeth Rosseel
Hartcentrum Aalst, AZorg, Aalst, Belgium
2 shared publications - Albert Chan
Division of Cardiology, Royal Columbian Hospital , New Westminster, BC
1 shared publication Beatriz Vaquerizo
Heart Disease Research Group Mar Hospital, Biomedical Research Institute of Mar Hospital (IMIM) Barcelona Spain
1 shared publication
Latest Publications
- Open Access
- 6 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Late outcomes of early discharge following transcatheter aortic valve implantation: results from the POLESTAR trial
Background: Early discharge (ED) within 48 h after transcatheter aortic valve implantation (TAVI) seems feasible and safe. The POLESTAR study demonstrated good 30-day outcomes of ED after TAVI using the ACURATE valve but also identified patients requiring prolonged hospitalization. Long-term outcomes after ED or prolonged hospitalization remain unknown. Aims: To determine the long-term impact of successful ED and prolonged hospitalization. Methods: POLESTAR was a prospective, multicentre, observational trial enrolling patients deemed eligible for ED prior to transfemoral TAVI with ACURATE Neo/Neo2. One-year outcomes were determined and compared between those who achieved ED and those who did not. The primary endpoint was a landmark analysis of major adverse cardiovascular events (MACE), including all-cause mortality, stroke, myocardial infarction, and cardiac rehospitalization, occurring between 30 days and oneyear post-procedure. Results: Among 252 patients from 15 sites in four countries, ED was achieved in 173 (69%) patients, while 79 (31%) required prolonged hospital stay (non-ED). One-year survival was 97%. Landmark 30-day analysis showed MACE occurring in 4.7% of ED patients vs 11.7% of non-ED patients at 1 year (HR 0.38[0.15–0.98] P = .045). Rehospitalization was numerically lower in the ED group (HR 0.56[0.27–1.19]; P = .13). Kansas City Cardiomyopathy Questionnaire (KCCQ) scores improved significantly in the full cohort (18.5 improvement; 95%CI: 15.9–21.0, P < .01), with no statistically significant difference between ED and non-ED cohorts (P for interaction = .30). Conclusions: An ED strategy after TAVI with ACURATE Neo was safe in selected patients without compromising longer-term outcomes or health-related quality of life. Patients who did not achieve ED experienced more MACE after 30 days (NCT03910751).
- 6 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Open AccessLate outcomes of early discharge following transcatheter aortic valve implantation: results from the POLESTAR trial
Background: Early discharge (ED) within 48 h after transcatheter aortic valve implantation (TAVI) seems feasible and safe. The POLESTAR study demonstrated good 30-day outcomes of ED after TAVI using the ACURATE valve but also identified patients requiring prolonged hospitalization. Long-term outcomes after ED or prolonged hospitalization remain unknown. Aims: To determine the long-term impact of successful ED and prolonged hospitalization. Methods: POLESTAR was a prospective, multicentre, observational trial enrolling patients deemed eligible for ED prior to transfemoral TAVI with ACURATE Neo/Neo2. One-year outcomes were determined and compared between those who achieved ED and those who did not. The primary endpoint was a landmark analysis of major adverse cardiovascular events (MACE), including all-cause mortality, stroke, myocardial infarction, and cardiac rehospitalization, occurring between 30 days and oneyear post-procedure. Results: Among 252 patients from 15 sites in four countries, ED was achieved in 173 (69%) patients, while 79 (31%) required prolonged hospital stay (non-ED). One-year survival was 97%. Landmark 30-day analysis showed MACE occurring in 4.7% of ED patients vs 11.7% of non-ED patients at 1 year (HR 0.38[0.15–0.98] P = .045). Rehospitalization was numerically lower in the ED group (HR 0.56[0.27–1.19]; P = .13). Kansas City Cardiomyopathy Questionnaire (KCCQ) scores improved significantly in the full cohort (18.5 improvement; 95%CI: 15.9–21.0, P < .01), with no statistically significant difference between ED and non-ED cohorts (P for interaction = .30). Conclusions: An ED strategy after TAVI with ACURATE Neo was safe in selected patients without compromising longer-term outcomes or health-related quality of life. Patients who did not achieve ED experienced more MACE after 30 days (NCT03910751).
- 1 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (5) , e016145
Rapid Atrial Pacing-Induced Wenckebach Atrioventricular Block: A Poor Predictor of Permanent Pacemaker Need Post-TAVR
BACKGROUND: The prognostic value of rapid atrial pacing (RAP)-induced Wenckebach atrioventricular block (W-AVB) as a diagnostic test for predicting permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) remains unclear and requires further validation. The objective of this study was to evaluate the predictive value of RAP-induced W-AVB for PPI and sudden cardiac death within 30 days post-TAVR. METHODS: This prospective, investigator-initiated, multicenter study (PACE-TAVR) included 640 patients undergoing TAVR across 12 centers. RAP was performed before and after TAVR to assess for W-AVB. Using negative predictive values and negative likelihood ratios, the predictive value of W-AVB was evaluated for the primary end point: sudden cardiac death or guideline-based indications for PPI, including complete AVB or alternating bundle branch block (Class I), and preexisting conduction disturbances with new ECG changes, new-onset left bundle branch block, a positive electrophysiology study, or sinus node dysfunction (Class II). RESULTS: RAP was successfully performed post-TAVR in 556 patients, with RAP-induced W-AVB observed in 192 (34.5%). W-AVB was associated with baseline conduction disturbances, amiodarone use, pre-TAVR RAP-induced W-AVB, and anesthesia type. The primary end point was more frequent in patients with W-AVB (15.6% versus 9.3%; odds ratio, 1.80 [95% CI, 1.06–3.04]; P =0.029). However, the absence of W-AVB had a negative predictive value of only 90.7% and a poor negative likelihood ratio (0.79). The test’s utility declined in subgroups at high risk for PPI, including self-expanding valve recipients (odds ratio, 1.47 [95% CI, 0.84–2.58]; negative predictive value, 88.4%; negative likelihood ratio, 0.86) and patients with a baseline or new left bundle branch block (odds ratio, 1.14 [95% CI, 0.54–2.42]; negative predictive value, 81.3%; negative likelihood ratio, 0.95). CONCLUSIONS: RAP-induced W-AVB demonstrates limited utility in predicting post-TAVR PPI or sudden cardiac death, particularly in patients at high risk for PPI. Clinicians should be cautious when using this test for post-TAVR rhythm management. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05278585.
- 1 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (5) , e016145
Rapid Atrial Pacing-Induced Wenckebach Atrioventricular Block: A Poor Predictor of Permanent Pacemaker Need Post-TAVR
BACKGROUND: The prognostic value of rapid atrial pacing (RAP)-induced Wenckebach atrioventricular block (W-AVB) as a diagnostic test for predicting permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) remains unclear and requires further validation. The objective of this study was to evaluate the predictive value of RAP-induced W-AVB for PPI and sudden cardiac death within 30 days post-TAVR. METHODS: This prospective, investigator-initiated, multicenter study (PACE-TAVR) included 640 patients undergoing TAVR across 12 centers. RAP was performed before and after TAVR to assess for W-AVB. Using negative predictive values and negative likelihood ratios, the predictive value of W-AVB was evaluated for the primary end point: sudden cardiac death or guideline-based indications for PPI, including complete AVB or alternating bundle branch block (Class I), and preexisting conduction disturbances with new ECG changes, new-onset left bundle branch block, a positive electrophysiology study, or sinus node dysfunction (Class II). RESULTS: RAP was successfully performed post-TAVR in 556 patients, with RAP-induced W-AVB observed in 192 (34.5%). W-AVB was associated with baseline conduction disturbances, amiodarone use, pre-TAVR RAP-induced W-AVB, and anesthesia type. The primary end point was more frequent in patients with W-AVB (15.6% versus 9.3%; odds ratio, 1.80 [95% CI, 1.06–3.04]; P =0.029). However, the absence of W-AVB had a negative predictive value of only 90.7% and a poor negative likelihood ratio (0.79). The test’s utility declined in subgroups at high risk for PPI, including self-expanding valve recipients (odds ratio, 1.47 [95% CI, 0.84–2.58]; negative predictive value, 88.4%; negative likelihood ratio, 0.86) and patients with a baseline or new left bundle branch block (odds ratio, 1.14 [95% CI, 0.54–2.42]; negative predictive value, 81.3%; negative likelihood ratio, 0.95). CONCLUSIONS: RAP-induced W-AVB demonstrates limited utility in predicting post-TAVR PPI or sudden cardiac death, particularly in patients at high risk for PPI. Clinicians should be cautious when using this test for post-TAVR rhythm management. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05278585.
- 1 May 2023
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 35 (5) , E234-E247
iFR/FFR/IVUS Discordance and Clinical Implications: Results From the Prospective Left Main Physiology Registry
This study aimed to assess discordance between results of iFR, FFR, and intravascular ultrasound in intermediate left main coronary lesions.
- 1 May 2023
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 35 (5) , E234-E247
iFR/FFR/IVUS Discordance and Clinical Implications: Results From the Prospective Left Main Physiology Registry
This study aimed to assess discordance between results of iFR, FFR, and intravascular ultrasound in intermediate left main coronary lesions.
- Open Access
- 1 February 2022
- Published by Elsevier in American Heart Journal
- Vol. 244, 19-30
Distal versus conventional radial access for coronary angiography and intervention: Design and rationale of DISCO RADIAL study
- 1 February 2022
- Published by Elsevier in American Heart Journal
- Vol. 244, 19-30
Open AccessDistal versus conventional radial access for coronary angiography and intervention: Design and rationale of DISCO RADIAL study
- Open Access
- 16 November 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (22) , e022123
Coronary Endothelium‐Dependent Vasomotor Function After Drug‐Eluting Stent and Bioresorbable Scaffold Implantation
Background: Early generation drug‐eluting stents (DESs) showed a high grade of coronary endothelial dysfunction that was attributed to lack of stent reendothelialization. Endothelium‐dependent vasomotor response of current DESs and bioresorbable scaffolds (BRSs) remains unknown. This study sought to assess the device‐related endothelial function of current devices and to correlate neointima healing with endothelial function. Methods and Results: A total of 206 patients from 4 randomized trials treated with the durable‐polymer everolimus‐eluting Xience (n=44), bioresorbable‐polymer sirolimus‐eluting Orsiro (n=35), polymer‐free biolimus‐eluting Biofreedom (n=24), bioactive endothelial‐progenitor cell‐capturing sirolimus‐eluting Combo DES (n=25), polymer‐based everolimus‐eluting Absorb (n=44), and Mg‐based sirolimus‐eluting Magmaris BRS (n=34) underwent endothelium‐dependent vasomotor tests and optical coherence tomography imaging, as per protocol, at follow‐up. Crude vasomotor responses of distal segments to low‐dose acetylcholine (10 −6 mol/L) were different between groups: bioresorbablepolymer DEShad the worst (−8.4%±12.6%) and durable‐polymer DES had the most physiologic (−0.4%±11.8%; P =0.014). High‐dose acetylcholine (10 −4 mol/L) showed similar responses between groups (ranging from −10.8%±11.6% to −18.1%±15.4%; P =0.229). Device healing was different between devices. Uncovered struts ranged from 6.3%±7.1% (bioresorbable‐polymer DES) to 2.5%±4.5% (bioactive DES; P =0.056). In multivariate models, endothelium‐dependent vasomotor response was associated with age, bioresorbable‐polymer DES, and angiographic lumen loss, but not with strut coverage nor plaque type. Endothelial dysfunction (defined as ≥4% vasoconstriction) was observed in 46.6% of patients with low‐dose and 68.9% with high‐dose acetylcholine, without differences between groups. Conclusions: At follow‐up, endothelial dysfunction was frequently observed in distal segments treated with current stents without remarkable differences between devices. Although neointima healing was different between devices, poor healing was not associated with endothelial dysfunction.
- 16 November 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (22) , e022123
Open AccessCoronary Endothelium‐Dependent Vasomotor Function After Drug‐Eluting Stent and Bioresorbable Scaffold Implantation
Background: Early generation drug‐eluting stents (DESs) showed a high grade of coronary endothelial dysfunction that was attributed to lack of stent reendothelialization. Endothelium‐dependent vasomotor response of current DESs and bioresorbable scaffolds (BRSs) remains unknown. This study sought to assess the device‐related endothelial function of current devices and to correlate neointima healing with endothelial function. Methods and Results: A total of 206 patients from 4 randomized trials treated with the durable‐polymer everolimus‐eluting Xience (n=44), bioresorbable‐polymer sirolimus‐eluting Orsiro (n=35), polymer‐free biolimus‐eluting Biofreedom (n=24), bioactive endothelial‐progenitor cell‐capturing sirolimus‐eluting Combo DES (n=25), polymer‐based everolimus‐eluting Absorb (n=44), and Mg‐based sirolimus‐eluting Magmaris BRS (n=34) underwent endothelium‐dependent vasomotor tests and optical coherence tomography imaging, as per protocol, at follow‐up. Crude vasomotor responses of distal segments to low‐dose acetylcholine (10 −6 mol/L) were different between groups: bioresorbablepolymer DEShad the worst (−8.4%±12.6%) and durable‐polymer DES had the most physiologic (−0.4%±11.8%; P =0.014). High‐dose acetylcholine (10 −4 mol/L) showed similar responses between groups (ranging from −10.8%±11.6% to −18.1%±15.4%; P =0.229). Device healing was different between devices. Uncovered struts ranged from 6.3%±7.1% (bioresorbable‐polymer DES) to 2.5%±4.5% (bioactive DES; P =0.056). In multivariate models, endothelium‐dependent vasomotor response was associated with age, bioresorbable‐polymer DES, and angiographic lumen loss, but not with strut coverage nor plaque type. Endothelial dysfunction (defined as ≥4% vasoconstriction) was observed in 46.6% of patients with low‐dose and 68.9% with high‐dose acetylcholine, without differences between groups. Conclusions: At follow‐up, endothelial dysfunction was frequently observed in distal segments treated with current stents without remarkable differences between devices. Although neointima healing was different between devices, poor healing was not associated with endothelial dysfunction.